Welcome to our dedicated page for Sarepta Therapeutics news (Ticker: SRPT), a resource for investors and traders seeking the latest updates and insights on Sarepta Therapeutics stock.
Sarepta Therapeutics, Inc. develops and commercializes precision genetic medicines for rare diseases, with a central focus on Duchenne muscular dystrophy and other neuromuscular conditions. Company news commonly covers product revenue and commercialization trends for ELEVIDYS and PMO therapies, including AMONDYS 45, VYONDYS 53 and EXONDYS 51.
Updates also address FDA interactions for Duchenne therapies, clinical and biomarker data from the siRNA pipeline, and programs such as SRP-1001 for FSHD1 and SRP-1003 for DM1. Other recurring announcements include quarterly financial results, Nasdaq inducement equity grants, and patient-community initiatives tied to Duchenne muscular dystrophy.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced it earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT) after reaching the second development milestone in the Phase 1/2 study of ARO-DM1 (SRP-1003) for type 1 myotonic dystrophy.
The milestone followed a drug safety committee review, authorization to dose escalate, and attainment of a pre-specified patient enrollment target. Arrowhead said it expects to receive the payment within 60 days. The company reported cohort 4 (6 mg/kg) accrual is nearly complete and plans to begin enrollment in cohort 5 (12 mg/kg) in Q1 2026.
Sarepta (NASDAQ:SRPT) announced FDA approval of updated prescribing information for ELEVIDYS on November 14, 2025. Key label changes include a boxed warning for acute serious liver injury (ALI) and acute liver failure (ALF), removal of the non-ambulatory indication, expanded prescriber guidance with modified corticosteroid regimens, and enhanced weekly monitoring for 3 months post-infusion. The company plans to commence a study of an enhanced sirolimus immunosuppressive regimen to address ALI/ALF risk so dosing may resume for non-ambulatory patients with FDA concurrence. ELEVIDYS has been administered to over 1,100 patients globally.
Summary not available.
Sarepta Therapeutics (NASDAQ:SRPT) will report third quarter 2025 financial results after the Nasdaq Global Market closes on Monday, Nov. 3, 2025. A conference call to discuss results and recent corporate developments will follow at 4:30 p.m. ET.
The event will be webcast live via the investor relations site at https://investorrelations.sarepta.com/events-presentations and a replay will be archived there for one year. Phone participants must register online to receive dial-in details and a personal PIN by auto-generated email.
Sarepta Therapeutics (NASDAQ:SRPT) will present new clinical and real-world data at the 30th World Muscle Society Congress, Oct 7–11, 2025 in Vienna.
Presentations cover delandistrogene moxeparvovec (micro-dystrophin expression, safety, cardiac outcomes, mitigation of acute liver injury), a real-world pulmonary function study of casimersen, and EMERGENE phase 3 results for bidridistrogene xeboparvovec (SRP-9003) showing SGCB expression and safety in LGMD2E/R4. Multiple investigator-led delandistrogene abstracts (including sirolimus prophylaxis) will also be presented. Abstracts will be posted on Sarepta.com after the WMS embargo.
Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, has announced equity inducement grants to 8 new employees hired in Q3 2025. The grants, approved under the company's 2024 Employment Commencement Incentive Plan, consist of 49,805 restricted stock units (RSUs). These RSUs will vest over four years, with 25% vesting annually on the grant date anniversary, contingent on continued employment.
The equity awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by the Compensation Committee of Sarepta's Board of Directors.
Sarepta Therapeutics (NASDAQ:SRPT) has announced 25 recipients for its Route 79 Duchenne Scholarship Program for the 2025-2026 academic year. The program, now in its 8th year, will award $5,000 scholarships to 20 individuals living with Duchenne muscular dystrophy and 5 siblings of individuals with the condition.
The scholarship recipients were selected by an independent committee based on academic records, community involvement, personal essays, and recommendation letters. Since its inception, the program has awarded more than 150 scholarships. The program's name, Route 79, references the 79 exons of the dystrophin gene, which is linked to Duchenne muscular dystrophy.
Sarepta Therapeutics (NASDAQ:SRPT) has announced a significant refinancing of its convertible notes through privately negotiated exchange agreements. The company will exchange approximately $700 million of its 1.25% convertible senior notes due 2027 for new 4.875% convertible notes due 2030 worth $602 million, along with up to 6.7 million shares of common stock and $123.3 million in cash.
The new convertible notes have an initial conversion rate of 16.6667 shares per $1,000 principal amount, equivalent to a conversion price of approximately $60.00 per share, representing a 191.5% premium. Additionally, Sarepta entered into a private placement agreement with J. Wood Capital Advisors LLC for up to 1.4 million shares of common stock. The transactions are expected to close around August 28, 2025.
Sarepta Therapeutics (NASDAQ:SRPT) announced two significant financial transactions related to its siRNA collaboration with Arrowhead Pharmaceuticals. The company has sold 9,265,312 shares of Arrowhead stock in a block trade for $174 million in gross proceeds. Additionally, Sarepta will transfer 2,660,989 shares to Arrowhead to satisfy $50 million of a $100 million milestone payment.
The milestone payment was triggered by positive safety data review and achievement of enrollment targets in the Phase 1/2 study of SRP-1003, an RNAi therapeutic for type 1 myotonic dystrophy (DM1). Preliminary data from this study is expected in second half of 2025.
Sarepta Therapeutics (NASDAQ:SRPT) reported strong Q2 2025 financial results with total revenues of $611.1 million, up 68% year-over-year. The company achieved GAAP net income of $196.9 million and resumed ELEVIDYS shipments for ambulatory Duchenne patients following FDA review.
Key highlights include net product revenues of $513.1 million, a 42% increase year-over-year, and progress on their restructuring plan targeting over $100 million in cost savings through 2025. The company is advancing multiple siRNA programs with clinical readouts expected in 2025-2026 for FSHD, DM1, SCA2, and Huntington's Disease.
The strategic restructuring announced in July 2025 aims to reduce expenses by $400 million annually starting in 2026, positioning the company to repay its 2027 convertible notes while maintaining focus on high-impact programs.